Allergan announces another potential acquisition

10 January 2017
mergers-acquisitions-big

Dublin, Ireland-headquartered Allergan (NYSE: AGN) has purchased an option to acquire Lysosomal Therapeutics (LTI), a privately owned small molecule specialist based in the USA, which is focused on developing novel therapies against neurodegenerative diseases.

Its lead investigational compound LTI-291 targets Parkinson’s disease and related disorders. Under the terms of the agreement, Allergan purchased an option right directly from LTI shareholders to acquire the company following completion of its Phase I trial There was no indication of value of the potential purchase.

LTI-291 aims to stimulate the activity of glucocerebrosidase (GCase) in the brain. In several lysosomal storage diseases, the activity of GCase is reduced due to a genetic mutation, and it is hoped that activation of the enzyme will ameliorate disease progression in these patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology